A research article from Dr. Jinsong Zhang’s lab, entitled “The transcriptional corepressor CBFA2T3 inhibits all-trans-retinoic acid–induced myeloid gene expression and […]Read More
SLU Institute for Drug and Biotherapeutic Innovation
The Saint Louis University Institute for Drug and Biotherapeutic Innovation (SLU-IDBI) is a multidisciplinary association of researchers with a shared interest in drug and biotherapeutic discovery and development.
As primary drug discovery and development has moved from big pharma back into academia, SLU-IDBI members have skills that range the full spectrum of what is needed for drug discovery and development, including target identification and validation, primary drug screening, medicinal chemistry optimization of screening hits, pharmacological characterization and optimization of promising compounds, and clinical trials for novel therapeutics. We are interested in partnering with like-minded researchers in academia and industry.
Stay Up To Date
IDBI members, John Tavis, Ph.D. and Amelia Pinto, Ph.D., presented their research on “Challenges of Drug Development During the COVID-19 […]Read Full Article
Clinical Trial for experimental drug remdesivir, under the direction of IDBI member Dr.Sarah George, shows promising results for the reduction […]Read Full Article
Dr. Salvimini was recently awarded two NIH grants to study chemotherapy-induced cognitive impairment or “chemo-brain,” and unwanted side effects of […]Read Full Article
John Tavis, professor of molecular microbiology and immunology at SLU, has been studying the hepatitis B virus for 24 years […]Read Full Article
SLU researchers and IDBI members Silviya Zustiak and David Griggs have teamed up to study the properties of carbon nanotubes […]Read More